Ref ID: 18799
Author:
M. J. Vehreschild, MD (Doctor of Medicine) – Physician 1, K. Wahlers, MD – Physician1, A. Hamprecht, MD – Microbiologist 1, G. Fischer, PhD – Professor 2, S. de Hoog, PhD – Professor 3, J. Vehreschild, MD – Physician 1, M. Karthaus, MD – Physician 4,
Author address:
1Univ. Hosp. Cologne, Koeln, Germany, 2Hlth. Authorities, Stuttgart, Germany, 3CBS, Utrecht, Netherlands, 4Klin. Neuperlach, Munich, Germany.
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: We are coordinating a global registry for cases of rare invasive fungal diseases (IFD). Methods: Fungiscope – A Global Emerging Fungal Infection Registry uses a web-based electronic case form accessible via www.fungiscope.net. For inclusion in the registry we require positive cultures or histopathological, antigen or molecular genetic evidence of IFD and the associated clinical symptoms and signs. The data entered onto the registry include demographics, underlying conditions, neutrophil count, concomitant immunosuppressive medications, clinical signs and symptoms of IFD, site of infection, diagnostic tests performed, pathogen identification, antifungal treatment, surgical procedures performed, response to treatment, overall survival and attributable mortality. Results:
Overall, 268 cases have been completed. Zygomycetes (n=100; 37%), Fusarium spp. (n=46; 17%), yeasts (n=40; 15%), and Dematiaceae (n=32; 12%) were the most frequently registered pathogens. Chemotherapy or allogeneic stem cell transplantation for a haematological malignancy was the most predominant risk factor (n=125; 47%), as well as diabetes mellitus (n=64; 24%), stay at an ICU (n=48; 18%) and chronic renal disease (n=36; 13%). Sites of infection included the lung in 115 patients (43%), followed by blood stream infections (n=56; 21%), the sino-nasal region (n=43, 16%) and deep soft tissues (n=41; 15%). For 146 (54%) patients, a favourable outcome, defined as a complete or partial response to treatment of IFD was documented. Overall mortality and mortality attributable to IFD was 43% (n=116) and 31% (n=82), respectively. Conclusions: The clinical relevance of emerging IFD is increasing steadily. Further investigators are cordially invited to contribute to Fungiscope.
Abstract Number: M-338
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a